[A13-05] Fidaxomicin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Last updated 15.04.2013
Project no.:
A13-05
Commission:
Commission awarded on 15.01.2013 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones, Immune system and infections
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-25 | Fidaxomicin (Clostridioides difficile infection) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A13-23 | Addendum to Commission A13-05 (fidaxomicin) | Commission completed |